Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis)

Andrologia

Volumn 47, Issue 3, 2015, Pages 328-332

  Lokant, M T ^a   Naz, R K ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia; Prostate abnormalities; Prostate cancer; Prostatitis; PSA PSA antibodies

Indexed keywords

AUTOANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSTATE CANCER; PROSTATITIS; SERUM; WESTERN BLOTTING; BLOOD; IMMUNOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

AUTOANTIBODIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 84923584828     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/and.12265     Document Type: Article

References (23)

1. Alexander RB, Brady F, Ponniah S (1997) Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 50:893-899.
2. Balk SP, Ko Y, Bubley GJ (2003) Biology of prostate specific antigen. J Clin Oncol 21:383-391.
3. Cannon GW, Getzenberg RH (2008) Biomarkers for benign prostatic hyperplasia progression. Curr Urol Rep 9:279-283.
4. Chu TM, Kuriyama M, Johnson E, Papsidero LD, Killian CS, Murphy GP, Wang MC (1983) Circulating antibody to prostate antigen in patients with prostatic cancer. Ann N Y Acad Sci 417:383-389.
5. Collins MM, Stafford RS, O'Leary MP, Barry MJ (1998) How common is prostatitis? A national survey of physician visits. J Urol 159:1224-1228.
6. Hoover P, Naz RK (2012) Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma? Int J Androl 35:608-615.
7. Jain S, Bhojwani AG, Mellon JK (2002) Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J 78:646-650.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
9. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, Hauptmann S, Schnorr D, Loening SA (2000) Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer. Clin Chem 46:55-62.
10. Konig JE, Senge T, Allhoff EP, Konig W (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58:121-129.
11. Kramer G, Dieter M, Marberger M (2001) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202-1216.
12. Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 281:236-237.
13. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825-1829.
14. Miocinovic R, Bumbasirevic U, Djordjevic ML, Bojanic N, Milojevic B, Tulic C, Stephenson AJ (2013) Optimal use of prostate specific antigen for prostate cancer screening. Vojnosanit Pregl 70:501-503.
15. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratlift TL (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407-413.
16. Naz RK, Butler TS (2013) Antibodies to prostate-specific antigen in immunoinfertile women and men. J Reprod Immunol 97:217-222.
17. Nickel JC (1998) Prostatitis: myths and realities. Urology 51:362-366.
18. Oesterling JE (1996) Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 6:67-73.
19. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
20. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE (1992) Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66:96-107.
21. Whitmore WF, Gittes RF (1977) Studies on the prostate and testis as immunologically privileged sites. Cancer Treat Rep 61:217-222.
22. Williams RM, Naz RK (2010) Novel biomarkers and therapeutic targets for prostate cancer. Front Biosci S2:677-684.
23. Zisman A, Zisman E, Lindner A, Velikanov S, Siegel YI, Mozes E (1995) Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol 154:1052-1055.